Liposome-encapsulated gentamicin treatment of Mycobacterium avium- Mycobacterium intracellulare complex bacteremia in AIDS patients

58Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

TLC G-65, a liposome-encapsulated gentamicin, was given intravenously twice weekly for 4 weeks to AIDS patients with Mycobacterium avium-M. intracellulare complex (MAC) bacteremia at 1.7 mg of gentamicin per kg of body weight per infusion (4 patients), 3.4 mg/kg (10 patients), and 5.1 mg/kg (7 patients). MAC colony counts in blood fell by 75% or more in all three groups (P < 0.005). Drug resistance did not emerge during the study period. Transient renal insufficiency developed in one patient; no other adverse effects were detected. Liposome-encapsulated gentamicin is a potential therapy for MAC infections in AIDS patients.

Cite

CITATION STYLE

APA

Nightingale, S. D., Saletan, S. L., Swenson, C. E., Lawrence, A. J., Watson, D. A., Pilkiewicz, F. G., … Cal, S. X. (1993). Liposome-encapsulated gentamicin treatment of Mycobacterium avium- Mycobacterium intracellulare complex bacteremia in AIDS patients. Antimicrobial Agents and Chemotherapy, 37(9), 1869–1872. https://doi.org/10.1128/AAC.37.9.1869

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free